• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Final results of a randomized multicenter phase II study of alvocidib, cytarabine, and mitoxantrone versus cytarabine and daunorubicin (7 + 3) in newly diagnosed high-risk acute myeloid leukemia (AML).

作者信息

Zeidner Joshua F, Foster Matthew C, Blackford Amanda L, Litzow Mark R, Morris Lawrence E, Strickland Stephen A, Lancet Jeffrey E, Bose Prithviraj, Levy M Yair, Tibes Raoul, Gojo Ivana, Gocke Christopher D, Rosner Gary L, Little Richard F, Wright John J, Doyle L Austin, Smith B Douglas, Karp Judith E

机构信息

The Johns Hopkins Hospital, Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, United States; University of North Carolina, Lineberger Comprehensive Cancer Center, Chapel Hill, NC, United States.

University of North Carolina, Lineberger Comprehensive Cancer Center, Chapel Hill, NC, United States.

出版信息

Leuk Res. 2018 Sep;72:92-95. doi: 10.1016/j.leukres.2018.08.005. Epub 2018 Aug 10.

DOI:10.1016/j.leukres.2018.08.005
PMID:30118897
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7169946/
Abstract
摘要

相似文献

1
Final results of a randomized multicenter phase II study of alvocidib, cytarabine, and mitoxantrone versus cytarabine and daunorubicin (7 + 3) in newly diagnosed high-risk acute myeloid leukemia (AML).一项关于阿沃西地布、阿糖胞苷和米托蒽醌对比阿糖胞苷和柔红霉素（7+3）用于新诊断高危急性髓系白血病（AML）的随机多中心II期研究的最终结果。
Leuk Res. 2018 Sep;72:92-95. doi: 10.1016/j.leukres.2018.08.005. Epub 2018 Aug 10.
2
Randomized multicenter phase II study of flavopiridol (alvocidib), cytarabine, and mitoxantrone (FLAM) versus cytarabine/daunorubicin (7+3) in newly diagnosed acute myeloid leukemia.随机多中心II期研究：氟吡咯醇（阿沃西地布）、阿糖胞苷和米托蒽醌（FLAM）对比阿糖胞苷/柔红霉素（7+3）治疗新诊断的急性髓系白血病
Haematologica. 2015 Sep;100(9):1172-9. doi: 10.3324/haematol.2015.125849. Epub 2015 May 28.
3
Phase I Study of Alvocidib Followed by 7+3 (Cytarabine + Daunorubicin) in Newly Diagnosed Acute Myeloid Leukemia.阿糖胞苷+柔红霉素 7+3 方案序贯艾罗替尼治疗初治急性髓系白血病的 I 期临床研究
Clin Cancer Res. 2021 Jan 1;27(1):60-69. doi: 10.1158/1078-0432.CCR-20-2649. Epub 2020 Sep 30.
4
Sequential flavopiridol, mitoxantrone and cytosine arabinoside for newly diagnosed poor risk acute myeloid leukemia. What to do next?序贯使用氟吡汀、米托蒽醌和阿糖胞苷治疗新诊断的高危急性髓系白血病。接下来该怎么做？
Leuk Res. 2010 Jul;34(7):856-7. doi: 10.1016/j.leukres.2010.03.008. Epub 2010 Apr 7.
5
Intermediate-dose cytarabine plus mitoxantrone versus standard-dose cytarabine plus daunorubicin for acute myeloid leukemia in elderly patients.中剂量阿糖胞苷联合米托蒽醌与标准剂量阿糖胞苷联合柔红霉素治疗老年急性髓系白血病的比较。
Ann Oncol. 2018 Apr 1;29(4):973-978. doi: 10.1093/annonc/mdy030.
6
Randomized phase II study of two schedules of flavopiridol given as timed sequential therapy with cytosine arabinoside and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemia.随机Ⅱ期研究两种方案的 flavopiridol 与阿糖胞苷和米托蒽醌序贯疗法用于新诊断的、不良预后的成人急性髓系白血病。
Haematologica. 2012 Nov;97(11):1736-42. doi: 10.3324/haematol.2012.062539. Epub 2012 Jun 24.
7
Mitoxantrone and cytarabine versus daunorubicin and cytarabine in previously untreated patients with acute myeloid leukemia.米托蒽醌与阿糖胞苷联合方案对比柔红霉素与阿糖胞苷联合方案用于初治急性髓系白血病患者的疗效
Cancer Chemother Pharmacol. 1991;28(6):480-3. doi: 10.1007/BF00685827.
8
High-dose cytarabine consolidation with or without additional amsacrine and mitoxantrone in acute myeloid leukemia: results of the prospective randomized AML2003 trial.大剂量阿糖胞苷巩固治疗联合或不联合安吖啶和米托蒽醌治疗急性髓系白血病：前瞻性随机 AML2003 试验的结果。
J Clin Oncol. 2013 Jun 10;31(17):2094-102. doi: 10.1200/JCO.2012.46.4743. Epub 2013 Apr 29.
9
Continuous 24-h monitoring of electrocardiogram during anthracycline-based therapy in acute leukemia.急性白血病蒽环类药物治疗期间的24小时连续心电图监测。
Leuk Res. 2009 Aug;33(8):e109-10. doi: 10.1016/j.leukres.2008.12.024. Epub 2009 Feb 23.
10
[Treating patients with acute myeloid leukemias (AML) according to the protocol of the AML-01.10 Russian multicenter randomized trial: the coordinating center's results].[按照AML-01.10俄罗斯多中心随机试验方案治疗急性髓系白血病（AML）患者：协调中心的结果]
Ter Arkh. 2014;86(7):14-23.

引用本文的文献

1
Potential anticancer effects and toxicity of flavones luteolin and apigenin .黄酮类化合物木犀草素和芹菜素的潜在抗癌作用及毒性
J Environ Sci Health C Toxicol Carcinog. 2025 Jul 9:1-37. doi: 10.1080/26896583.2025.2527437.
2
Combined therapy with DR5-targeting antibody-drug conjugate and CDK inhibitors as a strategy for advanced colorectal cancer.以靶向DR5的抗体药物偶联物与CDK抑制剂联合治疗作为晚期结直肠癌的一种策略。
Cell Rep Med. 2025 Jun 17;6(6):102158. doi: 10.1016/j.xcrm.2025.102158. Epub 2025 May 30.
3
Systematic and comprehensive insights into HIF-1 stabilization under normoxic conditions: implications for cellular adaptation and therapeutic strategies in cancer.对常氧条件下HIF-1稳定化的系统全面见解：对癌症细胞适应和治疗策略的启示
Cell Mol Biol Lett. 2025 Jan 6;30(1):2. doi: 10.1186/s11658-024-00682-7.
4
Spatial transcriptomics reveals distinct and conserved tumor core and edge architectures that predict survival and targeted therapy response.空间转录组学揭示了不同且保守的肿瘤核心和边缘结构，这些结构可预测患者的生存和靶向治疗反应。
Nat Commun. 2023 Aug 18;14(1):5029. doi: 10.1038/s41467-023-40271-4.
5
Inhibition of multiple CDKs potentiates colon cancer chemotherapy via p73-mediated DR5 induction.抑制多种细胞周期蛋白依赖性激酶通过 p73 介导的 DR5 诱导增强结肠癌化疗效果。
Oncogene. 2023 Mar;42(12):869-880. doi: 10.1038/s41388-023-02598-6. Epub 2023 Jan 31.
6
Novel benzo chromene derivatives: design, synthesis, molecular docking, cell cycle arrest, and apoptosis induction in human acute myeloid leukemia HL-60 cells.新型苯并色烯衍生物的设计、合成、分子对接及对人急性髓系白血病 HL-60 细胞的细胞周期阻滞和凋亡诱导作用。
J Enzyme Inhib Med Chem. 2023 Dec;38(1):405-422. doi: 10.1080/14756366.2022.2151592.
7
Treatment options for acute myeloid leukemia patients aged <60 years.60岁以下急性髓系白血病患者的治疗选择。
Front Oncol. 2022 Oct 5;12:897220. doi: 10.3389/fonc.2022.897220. eCollection 2022.
8
Super enhancers: Pathogenic roles and potential therapeutic targets for acute myeloid leukemia (AML).超级增强子：急性髓系白血病（AML）的致病作用及潜在治疗靶点
Genes Dis. 2022 Mar 23;9(6):1466-1477. doi: 10.1016/j.gendis.2022.01.006. eCollection 2022 Nov.
9
An Overview of the Recent Development of Anticancer Agents Targeting the HIF-1 Transcription Factor.靶向缺氧诱导因子-1转录因子的抗癌药物最新进展概述
Cancers (Basel). 2021 Jun 4;13(11):2813. doi: 10.3390/cancers13112813.
10
Interrogation of novel CDK2/9 inhibitor fadraciclib (CYC065) as a potential therapeutic approach for AML.新型CDK2/9抑制剂法曲西利（CYC065）作为急性髓系白血病潜在治疗方法的研究
Cell Death Discov. 2021 Jun 10;7(1):137. doi: 10.1038/s41420-021-00496-y.

本文引用的文献

1
Clinical activity of alvocidib (flavopiridol) in acute myeloid leukemia.阿沃西地布（黄酮哌啶醇）在急性髓系白血病中的临床活性。
Leuk Res. 2015 Dec;39(12):1312-8. doi: 10.1016/j.leukres.2015.10.010. Epub 2015 Oct 19.
2
Randomized multicenter phase II study of flavopiridol (alvocidib), cytarabine, and mitoxantrone (FLAM) versus cytarabine/daunorubicin (7+3) in newly diagnosed acute myeloid leukemia.随机多中心II期研究：氟吡咯醇（阿沃西地布）、阿糖胞苷和米托蒽醌（FLAM）对比阿糖胞苷/柔红霉素（7+3）治疗新诊断的急性髓系白血病
Haematologica. 2015 Sep;100(9):1172-9. doi: 10.3324/haematol.2015.125849. Epub 2015 May 28.
3
Phase 2 trial of CPX-351, a fixed 5:1 molar ratio of cytarabine/daunorubicin, vs cytarabine/daunorubicin in older adults with untreated AML.CPX-351（阿糖胞苷/柔红霉素固定摩尔比为5:1）与阿糖胞苷/柔红霉素治疗未经治疗的老年急性髓系白血病的2期试验。
Blood. 2014 May 22;123(21):3239-46. doi: 10.1182/blood-2013-12-540971. Epub 2014 Mar 31.
4
Prognostic significance of the European LeukemiaNet standardized system for reporting cytogenetic and molecular alterations in adults with acute myeloid leukemia.欧洲白血病网络标准化系统报告成人急性髓细胞白血病细胞遗传学和分子改变的预后意义。
J Clin Oncol. 2012 Dec 20;30(36):4515-23. doi: 10.1200/JCO.2012.43.4738. Epub 2012 Sep 17.
5
Randomized phase II study of two schedules of flavopiridol given as timed sequential therapy with cytosine arabinoside and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemia.随机Ⅱ期研究两种方案的 flavopiridol 与阿糖胞苷和米托蒽醌序贯疗法用于新诊断的、不良预后的成人急性髓系白血病。
Haematologica. 2012 Nov;97(11):1736-42. doi: 10.3324/haematol.2012.062539. Epub 2012 Jun 24.
6
Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study.吉妥珠单抗奥佐米星治疗初治成人急性髓系白血病的疗效（ALFA-0701）：一项随机、开放标签、3 期研究。
Lancet. 2012 Apr 21;379(9825):1508-16. doi: 10.1016/S0140-6736(12)60485-1. Epub 2012 Apr 5.
7
Phase 1 and pharmacokinetic study of bolus-infusion flavopiridol followed by cytosine arabinoside and mitoxantrone for acute leukemias.氟维司群联合阿糖胞苷和米托蒽醌治疗急性白血病的 1 期及药代动力学研究。
Blood. 2011 Mar 24;117(12):3302-10. doi: 10.1182/blood-2010-09-310862. Epub 2011 Jan 14.
8
Clinical activity of sequential flavopiridol, cytosine arabinoside, and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemia.序贯氟达拉滨、阿糖胞苷和米托蒽醌治疗新诊断的高危成人急性髓系白血病的临床活性。
Leuk Res. 2010 Jul;34(7):877-82. doi: 10.1016/j.leukres.2009.11.007. Epub 2009 Dec 4.
9
Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet.成人急性髓系白血病的诊断和治疗：代表欧洲白血病网的国际专家小组的建议。
Blood. 2010 Jan 21;115(3):453-74. doi: 10.1182/blood-2009-07-235358. Epub 2009 Oct 30.
10
Anthracycline dose intensification in acute myeloid leukemia.急性髓系白血病中蒽环类药物剂量强化
N Engl J Med. 2009 Sep 24;361(13):1249-59. doi: 10.1056/NEJMoa0904544.